A Phase 3 interventional study of Denosumab in Bone Metastases in Men With Hormone-Refractory Prostate Cancer and Bone Metastases in Subjects With Advanced Breast Cancer, sponsored by Amgen. Completed at 64 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-24.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial will facilitate access to denosumab for adults with advanced cancer who have participated in a denosumab phase 3 study until denosumab is approved and available for sale.
10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.
This study's enrollment of 129 is above the median of 60 across 7,706 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab was approved and available for sale.
Drug: Denosumab
Administered by subcutaneous injection every 4 weeks (Q4W)
Also known as: Xgeva
Number of Participants With Adverse Events
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. Each AE was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, where Grade 1 = Mild AE Grade 2 = Moderate AE Grade 3 = Severe AE Grade 4 = Life-threatening or disabling AE Grade 5 = Death related to AE. Treatment-related adverse events (TRAEs) includes events for which the investigator indicated there was a reasonable possibility they may have been caused by investigational product.
Time frame: From first dose of denosumab in Study 20110113 to end of study; median (minimum, maximum) time on study was 13.93 (0.0, 74.7) months.
Number of Participants With Anti-denosumab Binding Antibodies
A blood sample was collected at the end of study visit for the measurement of anti-denosumab binding antibodies.
Time frame: Assessed at end of study; the median (minimum, maximum) time on study for all enrolled participants was 13.9 (0.0, 74.7) months.
This study was conducted at 65 centers in Europe, Latin America, Japan, and South Africa. Participants were enrolled from 22 November 2011 to 27 October 2014.
| Milestone | Denosumab |
|---|---|
| Started | 129 |
| Received denosumab | 128 |
| Completed | 4 |
| Not completed | 125 |
| Withdrew: Protocol-specified criteria | 62 |
| Withdrew: Adverse event | 19 |
| Withdrew: Death | 17 |
| Withdrew: Withdrawal by subject | 10 |
| Withdrew: Disease progression | 9 |
| Withdrew: Other | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Administrative decision | 1 |
| Withdrew: Noncompliance | 1 |
An adverse event (AE) is defined as any untoward medical occurrence in a clinical trial participant. The event does not necessarily have a causal relationship with study treatment. Each AE was graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, where Grade 1 = Mild AE Grade 2 = Moderate AE Grade 3 = Severe AE Grade 4 = Life-threatening or disabling AE Grade 5 = Death related to AE. Treatment-related adverse events (TRAEs) includes events for which the investigator indicated there was a reasonable possibility they may have been caused by investigational product.
| Participants | Denosumab |
|---|---|
| All adverse events | 98 |
| Serious adverse events | 45 |
| AE leading to discontinuation of denosumab | 28 |
| AE leading to discontinuation from study | 22 |
| Fatal adverse events | 18 |
| AE grade 3, 4, or 5 | 46 |
| Treatment-related adverse event | 26 |
| Treatment-related serious adverse event | 10 |
| TRAE leading to discontinuation of denosumab | 18 |
| TRAE leading to discontinuation from study | 16 |
| Treatment-related fatal adverse events | 0 |
| Treatment-related AE grade 3, 4, or 5 | 8 |
A blood sample was collected at the end of study visit for the measurement of anti-denosumab binding antibodies.
| Participants | Denosumab |
|---|---|
| Number of Participants With Anti-denosumab Binding Antibodies | 0 |
Collected over From first dose of denosumab in Study 20110113 to end of study. Median (minimum, maximum) time on study was 13.93 (0.0, 74.7) months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab | 18/128 (14.1%) | 45/128 (35.2%) | 66/128 (51.6%) |
| Event | Denosumab |
|---|---|
| Osteonecrosis of jawMusculoskeletal and connective tissue disorders | 7/128 |
| PneumoniaInfections and infestations | 4/128 |
| AnaemiaBlood and lymphatic system disorders | 3/128 |
| OsteomyelitisInfections and infestations | 3/128 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 3/128 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/128 |
| Abdominal painGastrointestinal disorders | 2/128 |
| AscitesGastrointestinal disorders | 2/128 |
| Intestinal obstructionGastrointestinal disorders | 2/128 |
| VomitingGastrointestinal disorders | 2/128 |
| Event | Denosumab |
|---|---|
| Back painMusculoskeletal and connective tissue disorders | 16/128 |
| NauseaGastrointestinal disorders | 15/128 |
| AstheniaGeneral disorders | 15/128 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/128 |
| Decreased appetiteMetabolism and nutrition disorders | 14/128 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 13/128 |
| FatigueGeneral disorders | 12/128 |
| DiarrhoeaGastrointestinal disorders | 11/128 |
| VomitingGastrointestinal disorders | 11/128 |
| Abdominal painGastrointestinal disorders | 9/128 |
| Age, Continuous(years) | Denosumab |
|---|---|
| Mean | 65.74 ± 11.48 |
| Age, Customized(Participants) | Denosumab |
|---|---|
| 18 - 64 years | 60 |
| 65 - 74 years | 36 |
| 75 - 84 years | 28 |
| ≥ 85 years | 5 |
| Sex: Female, Male(Participants) | Denosumab |
|---|---|
| Female | 97 |
| Male | 32 |
| Ethnicity (NIH/OMB)(Participants) | Denosumab |
|---|---|
| Hispanic or Latino | 28 |
| Not Hispanic or Latino | 101 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | Denosumab |
|---|---|
| White | 103 |
| Asian | 15 |
| Black or African American | 6 |
| Other | 4 |
| Unknown | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Nov 2011 to primary completion in Aug 2018, 80 months.
Results were first posted in Sep 2019, 1 year after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's 80 months is above that.
Counting every sponsor, half of 202 studies reached it within 50 months; a quarter within 33 and three quarters within 84.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab